Main clinical and molecular features of 14 sAPL patients
| Patient no. . | Age (y) at time of MS diagnosis . | Sex . | Primary disease . | Therapy of MS . | Latency between MS and APL, mo . | Latency between mitoxantrone and APL, mo . | Bcr subtype . | PML* breakpoint der(15)-der(17) . | RARA* breakpoint der(15)-der(17) . | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Type of treatment . | Mitoxantrone schedule . | Total dose, mg . | |||||||||
| UPN 1 | 59 | F | SPMS | Mitoxantrone | 10 mg/m2 every 1 mo | 30 | 13 | 10 | 1 | 1496-97 1496-97 | 6104-05 6104-05 |
| UPN 2 | 43 | F | SPMS | Mitoxantrone | 10 mg/m2 every 2 mo | 35 | 192 | 37 | 1 | 1657-60 1657-60 | 14446-49 14446-49 |
| UPN 3 | 56 | F | PPMS | Mitoxantrone | 10 mg/m2 every 3 mo | 70 | 30 | 4 | 1 | 1485-87 1485-87 | 15266-68 15266-68 |
| UPN 4 | 24 | F | RRMS | Mitoxantrone | 12 mg/m2 every 2 mo | 147 | 150 | 6 | 1 | 1922-23 1922-23 | 12418-19 12418-19 |
| UPN 5 | 21 | F | RRMS | Mitoxantrone | 12 mg/m2 every 2 mo | 170 | 66 | 18 | 1 | 1150-51 1169-70 | 14082-83 14054-55 |
| UPN 6 | 53 | F | RRMS | Mitoxantrone | 10 mg/m2 (every 1 mo, 3 doses), 10 mg/m2 (every 3 mo, 7 doses) | 234 | 72 | 51 | 1 | 1483-84 1484-85 | 12909-10 12908-09 |
| UPN 7 | 25 | M | RRMS | Mitoxantrone | 12 mg/m2 (every 1 mo, 3 doses), 6 mg/m2 (every 3 mo, 5 doses) | 110 | 37 | 27 | 1 | 1165 1161 | 7974 7978 |
| UPN 8 | 44 | M | SPMS | Mitoxantrone | 1.9 mg/m2 every 1 mo | 100 | 204 | 29 | 1 | 1409-10 1429-30 | 718-19 675-76 |
| UPN 9 | 33 | M | PPMS | Mitoxantrone | 10 mg/m2 every 2 mo | 176 | 144 | 30 | 3 | 1286-87 1286-87 | 15386-87 15386-87 |
| UPN 10 | 26 | M | RRMS | INF beta | NA | NA | 18 | NA | 3 | 1117-22† | 14920-25 |
| UPN 11 | 37 | M | RRMS | Mitoxantrone | 13 mg monthly (5 doses) | 81 | 97 | 17 | 1 | 1483-86 1486-1506 | 11586-89 11683-84 |
| UPN 12 | 49 | M | RRMS | Prednisone | NA | NA | 216 | NA | 1 | 1489-91 1485 | 14785-87 14117 |
| UPN 13 | 45 | F | PPMS | Mitoxantrone | 8 mg/m2 every 1 mo | 64 | 120 | 60 | 1 | 1485-87 1486-88 | 11569-71 11569-71 |
| UPN 14 | 25 | F | SPMS | Mitoxantrone | 11.36 mg/m2 every 1 mo | 120 | 237 | 34 | 1 | 1488-89 1483-86 | 12038-39 12035-38 |
| Patient no. . | Age (y) at time of MS diagnosis . | Sex . | Primary disease . | Therapy of MS . | Latency between MS and APL, mo . | Latency between mitoxantrone and APL, mo . | Bcr subtype . | PML* breakpoint der(15)-der(17) . | RARA* breakpoint der(15)-der(17) . | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Type of treatment . | Mitoxantrone schedule . | Total dose, mg . | |||||||||
| UPN 1 | 59 | F | SPMS | Mitoxantrone | 10 mg/m2 every 1 mo | 30 | 13 | 10 | 1 | 1496-97 1496-97 | 6104-05 6104-05 |
| UPN 2 | 43 | F | SPMS | Mitoxantrone | 10 mg/m2 every 2 mo | 35 | 192 | 37 | 1 | 1657-60 1657-60 | 14446-49 14446-49 |
| UPN 3 | 56 | F | PPMS | Mitoxantrone | 10 mg/m2 every 3 mo | 70 | 30 | 4 | 1 | 1485-87 1485-87 | 15266-68 15266-68 |
| UPN 4 | 24 | F | RRMS | Mitoxantrone | 12 mg/m2 every 2 mo | 147 | 150 | 6 | 1 | 1922-23 1922-23 | 12418-19 12418-19 |
| UPN 5 | 21 | F | RRMS | Mitoxantrone | 12 mg/m2 every 2 mo | 170 | 66 | 18 | 1 | 1150-51 1169-70 | 14082-83 14054-55 |
| UPN 6 | 53 | F | RRMS | Mitoxantrone | 10 mg/m2 (every 1 mo, 3 doses), 10 mg/m2 (every 3 mo, 7 doses) | 234 | 72 | 51 | 1 | 1483-84 1484-85 | 12909-10 12908-09 |
| UPN 7 | 25 | M | RRMS | Mitoxantrone | 12 mg/m2 (every 1 mo, 3 doses), 6 mg/m2 (every 3 mo, 5 doses) | 110 | 37 | 27 | 1 | 1165 1161 | 7974 7978 |
| UPN 8 | 44 | M | SPMS | Mitoxantrone | 1.9 mg/m2 every 1 mo | 100 | 204 | 29 | 1 | 1409-10 1429-30 | 718-19 675-76 |
| UPN 9 | 33 | M | PPMS | Mitoxantrone | 10 mg/m2 every 2 mo | 176 | 144 | 30 | 3 | 1286-87 1286-87 | 15386-87 15386-87 |
| UPN 10 | 26 | M | RRMS | INF beta | NA | NA | 18 | NA | 3 | 1117-22† | 14920-25 |
| UPN 11 | 37 | M | RRMS | Mitoxantrone | 13 mg monthly (5 doses) | 81 | 97 | 17 | 1 | 1483-86 1486-1506 | 11586-89 11683-84 |
| UPN 12 | 49 | M | RRMS | Prednisone | NA | NA | 216 | NA | 1 | 1489-91 1485 | 14785-87 14117 |
| UPN 13 | 45 | F | PPMS | Mitoxantrone | 8 mg/m2 every 1 mo | 64 | 120 | 60 | 1 | 1485-87 1486-88 | 11569-71 11569-71 |
| UPN 14 | 25 | F | SPMS | Mitoxantrone | 11.36 mg/m2 every 1 mo | 120 | 237 | 34 | 1 | 1488-89 1483-86 | 12038-39 12035-38 |
UPN indicates unique patient number (some details regarding UPNs 1, 4 and 5, and 7 were reported in references 20, 17, and 5, respectively); RRMS, relapsing-remitting multiple sclerosis; SPMS, secondary progressive multiple sclerosis; PPMS, primary progressive multiple sclerosis; and NA, not applicable.
Breakpoint locations are numbered according to the following GenBank accession numbers: PML intron 6 (bcr 1), S57791; PML intron 3 (bcr 3), S51489; and RARA intron 2, AJ297538.
No DNA was available to sequence the reciprocal RARA-PML in this case.